198 related articles for article (PubMed ID: 7670119)
1. Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging.
Douay L; Hu C; Giarratana MC; Bouchet S; Conlon J; Capizzi RL; Gorin NC
Blood; 1995 Oct; 86(7):2849-55. PubMed ID: 7670119
[TBL] [Abstract][Full Text] [Related]
2. Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation.
Carlo-Stella C; Mangoni L; Almici C; Garau D; Craviotto L; Piovani G; Caramatti C; Rizzoli V
Exp Hematol; 1992 Mar; 20(3):328-33. PubMed ID: 1568448
[TBL] [Abstract][Full Text] [Related]
3. Amifostine (WR-2721) protects normal haematopoietic stem cells against cyclophosphamide derivatives' toxicity without compromising their antileukaemic effects.
Douay L; Hu C; Giarratana MC; Gorin NC
Eur J Cancer; 1995; 31A Suppl 1():S14-6. PubMed ID: 7577094
[TBL] [Abstract][Full Text] [Related]
4. Ex vivo pharmacological purging of leukapheresis collections with nitrogen mustard: amifostine pretreatment improves both early and late peripheral blood progenitor cell recovery.
Poloni A; Leoni P; Curzi L; Cantori I; Mancini S; Montanari M; Masia MC; Olivieri A
Exp Hematol; 1999 Oct; 27(10):1548-56. PubMed ID: 10517497
[TBL] [Abstract][Full Text] [Related]
5. The potential role of amifostine (Ethyol) in haematological malignancies.
Gorin NC
Eur J Cancer; 1996; 32A Suppl 4():S31-9. PubMed ID: 8976820
[TBL] [Abstract][Full Text] [Related]
6. In vitro marrow purging in chronic myelogenous leukemia: effect of mafosfamide and recombinant granulocyte--macrophage colony-stimulating factor.
Carlo-Stella C; Mangoni L; Piovani G; Almici C; Garau D; Caramatti C; Rizzoli V
Bone Marrow Transplant; 1991 Oct; 8(4):265-73. PubMed ID: 1756324
[TBL] [Abstract][Full Text] [Related]
7. Purging of G-CSF-mobilized peripheral autografts in acute leukemia with mafosfamide and amifostine to protect normal progenitor cells.
Fauth F; Martin H; Sonnhoff S; Bialleck H; Wiesneth M; Mihanovic B; Hoelzer D
Bone Marrow Transplant; 2000 Apr; 25(8):831-6. PubMed ID: 10808203
[TBL] [Abstract][Full Text] [Related]
8. Ex vivo expansion of normal progenitor cells from acute myeloid leukemia cell-contaminated CD34+ peripheral blood progenitor cells after mafosfamide purging.
Stilz R; Grünebach F; Bader P; Vogel W; Kanz L; Brugger W; Scheding S
J Hematother Stem Cell Res; 2001 Dec; 10(6):777-85. PubMed ID: 11798504
[TBL] [Abstract][Full Text] [Related]
9. Comparative effects of amifostine (Ethyol) on normal hematopoietic stem cells versus human leukemic cells during ex vivo purging in autologous bone marrow transplants.
Douay L; Hu C; Giarratana MC; Gorin NC
Semin Oncol; 1994 Oct; 21(5 Suppl 11):16-20. PubMed ID: 7973773
[TBL] [Abstract][Full Text] [Related]
10. Effect of recombinant human stem cell factor on mafosfamide-treated bone marrow clonogenic cells.
Carlo-Stella C; Mangoni L; Almici C; Caramatti C; Rizzoli V
Stem Cells; 1993 Jul; 11 Suppl 2():170-4. PubMed ID: 7691323
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the protection of murine bone marrow stem cells by WR-2721 during in vitro treatment with mafosfamide.
Jiang R; Bony V; Lopez M
Prog Clin Biol Res; 1994; 389():23-9. PubMed ID: 7700906
[No Abstract] [Full Text] [Related]
12. Use of recombinant human granulocyte-macrophage colony-stimulating factor in patients with lymphoid malignancies transplanted with unpurged or adjusted-dose mafosfamide-purged autologous marrow.
Carlo-Stella C; Mangoni L; Almici C; Cottafavi L; Meloni G; Mandelli F; Rizzoli V
Blood; 1992 Nov; 80(9):2412-8. PubMed ID: 1421413
[TBL] [Abstract][Full Text] [Related]
13. Ex vivo manipulation of hematopoietic stem cells for transplantation: the potential role of amifostine.
Balzarotti M; Grisanti S; Granzow K; Saladini A; Sala A; Nozza A; Molteni A; Passamonti F; Carlo-Stella C; Santoro A; Siena S
Semin Oncol; 1999 Apr; 26(2 Suppl 7):66-71. PubMed ID: 10348263
[TBL] [Abstract][Full Text] [Related]
14. Successful mafosfamide purging of bone marrow from chronic myelogenous leukemia (CML) cells.
Nieborowska-Skórska M; Skórski T; Ratajczak MZ; Szczylik C; Malaguarnera L; Calabretta B
Folia Histochem Cytobiol; 1993; 31(4):161-7. PubMed ID: 8137996
[TBL] [Abstract][Full Text] [Related]
15. Effect of Ethiofos on cytotoxicity of pharmacological purging protocols used for autologous marrow grafts in acute lymphoblastic leukemia.
Skala JP; Rogers PC; Chan KW; Rodriguez WC
Prog Clin Biol Res; 1992; 377():57-62. PubMed ID: 1332075
[No Abstract] [Full Text] [Related]
16. Plasma interacts with mafosfamide toxicity to normal haematopoietic progenitor cells: impact on in vitro marrow purging.
Giarratana MC; Gorin NC; Douay L
Nouv Rev Fr Hematol (1978); 1995; 37(2):125-30. PubMed ID: 7644349
[TBL] [Abstract][Full Text] [Related]
17. Use of amifostine in bone marrow purging.
Cagnoni PJ; Jones RB; Bearman SI; Ross M; Hami L; Franklin WA; Capizzi R; Schein PS; Shpall EJ
Semin Oncol; 1996 Aug; 23(4 Suppl 8):44-8. PubMed ID: 8783666
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological purging of minimal residual disease from peripheral blood stem cell collections of acute myeloblastic leukemia patients: preclinical studies.
Motta MR; Mangianti S; Rizzi S; Ratta M; Campanini E; Fortuna A; Fogli M; Tura S; Lemoli RM
Exp Hematol; 1997 Nov; 25(12):1261-9. PubMed ID: 9357970
[TBL] [Abstract][Full Text] [Related]
19. Mafosfamide induces less sister chromatid exchange in Ph-positive cells than in normal bone marrow.
Becher R; Becker G; Schmidt CG
Haematol Blood Transfus; 1990; 33():133-6. PubMed ID: 2323626
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological-mediated purging with mafosfamide in acute and chronic myeloid leukemias. The Italian Study Group.
Rizzoli V; Mangoni L
Prog Clin Biol Res; 1990; 333():21-36; discussion 37-8. PubMed ID: 2308982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]